A brief dive into the phenomenon of cisplatin resistance in non-small-cell lung cancer

Maciej Sobczak

doi:10.18778/1730-2366.16.12

Authors

Maciej Sobczak University of Lodz, Faculty of Biology and Environmental Protection, Department of General Biophysics, Pomorska 141/143, 90-236 Lodz, Poland https://orcid.org/0000-0002-7377-6796

DOI:

https://doi.org/10.18778/1730-2366.16.12

Keywords:

non-small-cell lung cancer, cisplatin, cisplatin resistance

Abstract

Lung cancer is one of the most lethal types of cancer due to a lack of proper treatment. The rare presence of molecular therapy targets forces the use of platinum-based drugs. Cisplatin, approved by the USA as an anticancer therapy in the 1970s, is still one of the most prominent therapies against lung cancer. Unfortunately, the biggest limitation of cisplatin-based therapy is the development of cisplatin resistance. Cancer cells overcome the vast DNA damage caused by the drug in a variety of ways such as detoxication and extracellular transport of the drug, enhanced repair mechanisms, omitting apoptosis and epigenetic alterations. Chemotherapy resistance is an issue that so far cannot be dealt with. Nevertheless, better understanding of the molecular pathways behind cisplatin resistance brings hope for better therapy outcomes in lung cancer patients.

Downloads

Download data is not yet available.

References

Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., Patrick, S.M. 2010. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells. DNA Repair (Amst), 9: 745–753.
Google Scholar DOI: https://doi.org/10.1016/j.dnarep.2010.03.010

Dela Cruz, C.S., Tanoue, L.T., Matthay, R.A. 2011. Lung cancer: Epidemiology, etiology, and prevention. Clinics in Chest Medicine, 32(4): 605–644.
Google Scholar DOI: https://doi.org/10.1016/j.ccm.2011.09.001

Fadejeva, I., Olschewski, H., Hrzenjak, A. 2017. MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas. Oncotarget, 8(70): 115754–115773.
Google Scholar DOI: https://doi.org/10.18632/oncotarget.22975

Fennell, D.A., Summers, Y., Cadranel, J., Benepal, T., Christoph, D.C., Lal, R., Das, M., Maxwell, F., Visseren-Grul, C., Ferry, D. 2016. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews, 44: 42–50.
Google Scholar DOI: https://doi.org/10.1016/j.ctrv.2016.01.003

Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., Kroemer, G. 2012. Molecular mechanisms of cisplatin resistance. Oncogene, 31(15): 1869–1883.
Google Scholar DOI: https://doi.org/10.1038/onc.2011.384

Gąsiorkiewicz, B.M., Koczurkiewicz-Adamczyk, P., Piska, K., Pękala, E. 2021. Autophagy modulating agents as chemosensitizers for cisplatin therapy in cancer. Investigation New Drugs, 39: 538–563.
Google Scholar DOI: https://doi.org/10.1007/s10637-020-01032-y

He, Y., Chen, D., Yi, Y., Zeng, S., Liu, S., Li, P., Xie, H., Yu, P., Jiang, G., Liu, H. 2020. Histone deacetylase inhibitor sensitizes ERCC1-high non-small-cell lung cancer cells to cisplatin via regulating miR-149. Molecular Therapy – Oncolytics, 17: 448–459.
Google Scholar DOI: https://doi.org/10.1016/j.omto.2020.05.001

Hu, C., Zhang, M., Moses, N., Hu, C.-L., Polin, L., Chen, W., Jang, H., Heyza, J., Malysa, A., Caruso, J.A., Xiang, S., Patrick, S., Stemmer, P., Lou, Z., Bai, W., Wang, C., Bepler, G., Zhang, X.M. 2020. The USP10-HDAC6 axis confers cisplatin resistance in non-small cel lung cancer lacking wild-type p53. Cell Death & Disease, 11: 1–18.
Google Scholar DOI: https://doi.org/10.1038/s41419-020-2519-8

Lan, D., Wang, L., He, R., Ma, J., Bin, Y., Chi, X., Chen, G., Cai, Z. 2018. Exogenous glutathione contributes to cisplatin resistance in lung cancer A549 cells. American Journal of Translational Research, 10: 1295–1309.
Google Scholar

O’Byrne, K.J., Barr, M.P., Gray, S.G. 2011. The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers (Basel), 3(1): 1426–1453.
Google Scholar DOI: https://doi.org/10.3390/cancers3011426

Peklak-Scott, C., Smitherman, P.K., Townsend, A.J., Morrow, C.S. 2008. Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin. Molecular Cancer Therapeutics, 7(10): 3247–3255.
Google Scholar DOI: https://doi.org/10.1158/1535-7163.MCT-08-0250

Pizzorno, J. 2014. Glutathione! Integrative Medicine (Encinitas), 13: 8–12.
Google Scholar

Rocha, C.R.R., Silva, M.M., Quinet, A., Cabral-Neto, J.B., Menck, C.F.M. 2018. DNA repair pathways and cisplatin resistance: An intimate relationship. Clinics (Sao Paulo), 73(Suppl 1): e478s.
Google Scholar DOI: https://doi.org/10.6061/clinics/2018/e478s

Siegel, R.L., Miller, K.D., Fuchs, H.E., Jemal, A. 2021. Cancer statistics, 2021. C.A. Cancer Journal of Clinicians, 71: 7–33.
Google Scholar DOI: https://doi.org/10.3322/caac.21654

Sun, D.M., Tang, B.F., Li, Z.X., Guo, H.B., Cheng, J.L., Song, P.P., Zhao, X. 2018. miR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway. Scientific Reports, 8: 1–9.
Google Scholar DOI: https://doi.org/10.1038/s41598-018-26381-w

Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., Assempour, N., Iynkkaran, I., Liu, Y., Maciejewski, A., Gale, N., Wilson, A., Chin, L., Cummings, R., Le, D., Pon, A., Knox, C., Wilson, M. 2018. DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Research, 46: D1074–D1082.
Google Scholar DOI: https://doi.org/10.1093/nar/gkx1037

Wu, H.M., Jiang, Z.F., Ding, P.S., Shao, L.J., Liu, R.Y. 2015. Hypoxia-induced autophagy mediates cisplatin resistance in lung cancer cells. Scientific Reports, 5: 12291.
Google Scholar DOI: https://doi.org/10.1038/srep12291

Yun, C.W., Lee, S.H. 2018. The roles of autophagy in cancer. International Journal of Molecular Sciences, 19(11): 3466.
Google Scholar DOI: https://doi.org/10.3390/ijms19113466

Zappa, C., Mousa S.A. 2016. Non-small cell lung cancer: Current treatment and future advances. Translational Lung Cancer Research, 5: 288–300.
Google Scholar DOI: https://doi.org/10.21037/tlcr.2016.06.07